Alterola Biotech Inc. Issues Second Statement About Promotional Activity Concerning Its Common Stock

BIRKENHEAD, UK / ACCESSWIRE / October 21, 2021 / Alterola Biotech Inc. (OTC PINK:ABTI) today announced that it has been made aware of further promotional activity concerning ALTEROLA common stock. On October 12 and October 13, 2021, several articles were published in a newsletter owned, operated and edited by both MJ Capital, LLC, the Finance and Marketing Group LLC and PennyStockLocks, LLC. These articles declare that MJ Capital, the Finance and Marketing Group were paid up to Ten Thousand Dollars by ACN LLC for the two-day campaign.

The company has no connection with these articles and was in no way involved in the commission of any promotional activity of this type. The articles refer mainly to information the Company has published previously and it refers to market activity which are in no way a reflection of the Company position in relation to its Common Stock.

Similarly, the Company has become aware of statements issued by the Mina Mar Group declaring that ALTEROLA has agreed to participate in an Emerging Growth conference in Q4 2021.

ALTEROLA has not made any such agreements nor has it had any discussions with the Mina Mar Group on its performance or intended activities.

The Company first became aware of certain promotional activities concerning the Company and its common stock, after receiving notification from OTC Markets that online promotional reports encouraging the purchase of ALTEROLA shares may have had an impact on trading activity in the Company's securities. Until informed by OTC Markets, the Company was unaware of the promotional activity and remains unaware of the full nature and content of this activity, the extent of the dissemination or the parties involved. The Company is not affiliated in any way with the authors of the promotional activity identified by OTC Markets.

Certain statements contained in the promotional materials as supplied to the Company by OTC Markets may be materially false and/or misleading. The Company encourages those interested in the Company to rely solely on information included in its press releases combined with its filings and disclosures made with the U.S. Securities and Exchange Commission.

In its investigation into this matter, the Company has made inquiries of its executive officers, directors and controlling shareholders. The Company, its officers, directors and controlling shareholders, have not sold or purchased the Company's securities within the past 90 days. The Company states definitively that the Company, its officers, directors and, to the Company's knowledge, its controlling shareholders have not, directly or indirectly, authorized or been involved in any way with the creation or distribution of promotional materials of any kind.

Further, the Company has not, other than disclosed in its periodic reports filed with the Securities and Exchange Commission, issued any shares or convertible instruments allowing conversion to equity securities at prices constituting a discount to the current market rate at the time of the issuance.

Since January 1, 2021, the Company has not retained any third party services that provide investor relations services, public relations services, marketing, or other related services including the promotion of the Company or its securities.

About Alterola Biotech Inc.

ALTEROLA BIOTECH, INC. (OTC PINK:ABTI) is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary product platform across a broad range of therapeutic areas. The Company has a number of proprietary drug pipeline candidates including cannabinoids, cannabinoid-like molecules and non-cannabinoid molecules, which are under development for a range of indications. ABTI is also focused on producing quality, low cost of goods ingredients for the pharmaceutical, food and cosmetic sectors, from synthetic, biosynthetic and botanical sources. It is also focused on improving the drug delivery of such classes of compounds and has a range of proprietary technologies in development to enhance the delivery and bioavailability of its product portfolio. Geographically the Company has a presence in the UK, Ireland, Netherlands (Europe), USA, Australia, and China. If you would like more information about the Company, please visit our website https://alterola-abti.com/ or email our Investor Relations Department at [email protected].

Forward-Looking Statements

This news release contains forward-looking statements that reflect ALTEROLA's current expectations regarding future events, including statements regarding financial performance, the timing of preclinical studies and clinical trials, the timing and outcomes of regulatory or intellectual property decisions, the relevance of ALTEROLA product candidates currently in development. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of ALTEROLA's research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, and the potential acceptance of any future product that may (if ever) be approved by the appropriate regulatory authorities by consumer and medical professionals. A further list and description of risks and uncertainties associated with an investment in ALTEROLA can be found in ALTEROLA's filings with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. ALTEROLA undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Investor Relations Contact:
Seamus McAuley, CEO
Tel: +353 86 838 9812 or +445 7547560152
Email: [email protected] or [email protected]

SOURCE: Alterola Biotech, Inc.